AR042042A1 - Administracion combinada de una indolinona con un agente quimioterapeutico para trastornos de proliferacion celular - Google Patents
Administracion combinada de una indolinona con un agente quimioterapeutico para trastornos de proliferacion celularInfo
- Publication number
- AR042042A1 AR042042A1 ARP030104194A ARP030104194A AR042042A1 AR 042042 A1 AR042042 A1 AR 042042A1 AR P030104194 A ARP030104194 A AR P030104194A AR P030104194 A ARP030104194 A AR P030104194A AR 042042 A1 AR042042 A1 AR 042042A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- heteroaryl
- aryl
- cycloalkyl
- independently
- Prior art date
Links
- 239000002246 antineoplastic agent Substances 0.000 title abstract 5
- 229940127089 cytotoxic agent Drugs 0.000 title abstract 5
- 230000004663 cell proliferation Effects 0.000 title 1
- JYGFTBXVXVMTGB-UHFFFAOYSA-N indolin-2-one Chemical compound C1=CC=C2NC(=O)CC2=C1 JYGFTBXVXVMTGB-UHFFFAOYSA-N 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 10
- 125000003118 aryl group Chemical group 0.000 abstract 9
- 125000001072 heteroaryl group Chemical group 0.000 abstract 9
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 8
- 125000000623 heterocyclic group Chemical group 0.000 abstract 8
- 125000003545 alkoxy group Chemical group 0.000 abstract 6
- 125000004356 hydroxy functional group Chemical group O* 0.000 abstract 5
- 229910052739 hydrogen Inorganic materials 0.000 abstract 4
- 239000001257 hydrogen Substances 0.000 abstract 4
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 4
- 229910052760 oxygen Inorganic materials 0.000 abstract 4
- 206010028980 Neoplasm Diseases 0.000 abstract 3
- 201000011510 cancer Diseases 0.000 abstract 3
- -1 indolinone compound Chemical class 0.000 abstract 3
- 229910052757 nitrogen Inorganic materials 0.000 abstract 3
- 229910052717 sulfur Inorganic materials 0.000 abstract 3
- 229910052799 carbon Inorganic materials 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000001188 haloalkyl group Chemical group 0.000 abstract 2
- 150000004677 hydrates Chemical class 0.000 abstract 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 2
- 125000006413 ring segment Chemical group 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 239000012453 solvate Substances 0.000 abstract 2
- 102000014654 Aromatase Human genes 0.000 abstract 1
- 108010078554 Aromatase Proteins 0.000 abstract 1
- 102000029749 Microtubule Human genes 0.000 abstract 1
- 108091022875 Microtubule Proteins 0.000 abstract 1
- 229940127395 Ribonucleotide Reductase Inhibitors Drugs 0.000 abstract 1
- 239000012190 activator Substances 0.000 abstract 1
- 239000002168 alkylating agent Substances 0.000 abstract 1
- 229940100198 alkylating agent Drugs 0.000 abstract 1
- 125000004103 aminoalkyl group Chemical group 0.000 abstract 1
- 230000000340 anti-metabolite Effects 0.000 abstract 1
- 229940100197 antimetabolite Drugs 0.000 abstract 1
- 239000002256 antimetabolite Substances 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 125000004438 haloalkoxy group Chemical group 0.000 abstract 1
- 125000001475 halogen functional group Chemical group 0.000 abstract 1
- 230000002427 irreversible effect Effects 0.000 abstract 1
- 229940043355 kinase inhibitor Drugs 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 210000004688 microtubule Anatomy 0.000 abstract 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 abstract 1
- 239000000649 purine antagonist Substances 0.000 abstract 1
- 239000003790 pyrimidine antagonist Substances 0.000 abstract 1
- 230000003637 steroidlike Effects 0.000 abstract 1
- 239000003734 thymidylate synthase inhibitor Substances 0.000 abstract 1
- 229940044693 topoisomerase inhibitor Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Indole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42638602P | 2002-11-15 | 2002-11-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR042042A1 true AR042042A1 (es) | 2005-06-08 |
Family
ID=32326343
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP030104194A AR042042A1 (es) | 2002-11-15 | 2003-11-13 | Administracion combinada de una indolinona con un agente quimioterapeutico para trastornos de proliferacion celular |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20040152759A1 (https=) |
| EP (1) | EP1562600A4 (https=) |
| JP (1) | JP2006508981A (https=) |
| KR (1) | KR20050086594A (https=) |
| CN (2) | CN101259131A (https=) |
| AR (1) | AR042042A1 (https=) |
| AU (1) | AU2003290943A1 (https=) |
| BR (1) | BR0315630A (https=) |
| CA (1) | CA2506308A1 (https=) |
| CO (1) | CO5700778A2 (https=) |
| GT (1) | GT200300245A (https=) |
| MX (1) | MXPA05005150A (https=) |
| NL (1) | NL1024779C2 (https=) |
| NO (1) | NO20052578L (https=) |
| PA (1) | PA8588601A1 (https=) |
| PE (1) | PE20040835A1 (https=) |
| PL (1) | PL376954A1 (https=) |
| RU (1) | RU2342140C2 (https=) |
| TW (1) | TW200418837A (https=) |
| UY (1) | UY28081A1 (https=) |
| WO (1) | WO2004045523A2 (https=) |
| ZA (1) | ZA200503841B (https=) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60137273D1 (de) | 2000-10-20 | 2009-02-12 | Eisai R&D Man Co Ltd | Verfahren zur Herstellung von 4-Phenoxy chinolin Derivaten |
| ATE508747T1 (de) | 2003-03-10 | 2011-05-15 | Eisai R&D Man Co Ltd | C-kit kinase-hemmer |
| US7683172B2 (en) | 2003-11-11 | 2010-03-23 | Eisai R&D Management Co., Ltd. | Urea derivative and process for preparing the same |
| AU2005333515B2 (en) * | 2004-07-09 | 2012-05-10 | Arizona Board Of Regents, Acting On Behalf Of The University Of Arizona | Wortmannin analogs and methods of using same in combination with chemotherapeutic agents |
| AU2005283422C1 (en) * | 2004-09-17 | 2017-02-02 | Eisai R & D Management Co., Ltd. | Medicinal composition |
| US20090117197A1 (en) * | 2005-03-21 | 2009-05-07 | Vicus Therapeutics Llc | Compositions and methods for ameliorating cachexia |
| KR20070104673A (ko) * | 2005-03-23 | 2007-10-26 | 화이자 프로덕츠 인코포레이티드 | 암의 치료를 위한 항－ｃｔｌａ４ 항체와 인돌리논병용요법 |
| RU2007141654A (ru) * | 2005-05-12 | 2009-05-20 | Пфайзер Инк. (US) | Противоопухолевая комбинированная терапия, в которой используется сунитиниб-малат |
| AU2006255559B2 (en) * | 2005-06-03 | 2009-12-17 | Novartis Ag | Combination of pyrimidylaminobenzamide compounds and imatinib for treating or preventing proliferative diseases |
| EP1925941B1 (en) * | 2005-08-01 | 2012-11-28 | Eisai R&D Management Co., Ltd. | Method for prediction of the efficacy of vascularization inhibitor |
| WO2007015578A1 (ja) | 2005-08-02 | 2007-02-08 | Eisai R & D Management Co., Ltd. | 血管新生阻害物質の効果を検定する方法 |
| CA2620594C (en) * | 2005-09-01 | 2012-08-21 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition having improved disintegratability |
| CN101291950B (zh) * | 2005-09-15 | 2013-01-02 | 科学与工业研究会 | 咪唑基取代的类固醇和茚满-1-酮衍生物 |
| CN101267824A (zh) * | 2005-09-20 | 2008-09-17 | 辉瑞产品公司 | 使用酪氨酸激酶抑制剂的治疗剂型和方法 |
| CN101316590B (zh) * | 2005-11-07 | 2011-08-03 | 卫材R&D管理有限公司 | 血管生成抑制剂和c-kit激酶抑制剂的组合使用 |
| WO2007061130A1 (ja) * | 2005-11-22 | 2007-05-31 | Eisai R & D Management Co., Ltd. | 多発性骨髄腫に対する抗腫瘍剤 |
| RU2448708C3 (ru) * | 2006-05-18 | 2017-09-28 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Противоопухолевое средство против рака щитовидной железы |
| DE102006024834B4 (de) * | 2006-05-24 | 2010-07-01 | Schebo Biotech Ag | Neue Indol-Pyrrol-Derivate und deren Verwendungen |
| EP2044939A1 (en) * | 2006-06-29 | 2009-04-08 | Eisai R&D Management Co., Ltd. | Therapeutic agent for liver fibrosis |
| CN1899616A (zh) * | 2006-07-20 | 2007-01-24 | 中国人民解放军军事医学科学院生物工程研究所 | 非受体酪氨酸激酶c－Abl特异性抑制剂的新用途 |
| CN101511793B (zh) | 2006-08-28 | 2011-08-03 | 卫材R&D管理有限公司 | 针对未分化型胃癌的抗肿瘤剂 |
| CN101600694A (zh) | 2007-01-29 | 2009-12-09 | 卫材R&D管理有限公司 | 未分化型胃癌治疗用组合物 |
| US20090004213A1 (en) * | 2007-03-26 | 2009-01-01 | Immatics Biotechnologies Gmbh | Combination therapy using active immunotherapy |
| KR101513326B1 (ko) | 2007-11-09 | 2015-04-17 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 혈관 신생 저해 물질과 항종양성 백금 착물의 병용 |
| US7855204B2 (en) * | 2008-01-22 | 2010-12-21 | Concert Pharmaceuticals Inc. | Derivatives of gefitinib |
| AU2009210098B2 (en) * | 2008-01-29 | 2013-06-13 | Eisai R & D Management Co., Ltd. | Combined use of angiogenesis inhibitor and taxane |
| AU2009265360A1 (en) * | 2008-07-02 | 2010-01-07 | Generics [Uk] Limited | Preparation of 3-pyrrole substituted 2-indolinone derivatives |
| US20100143295A1 (en) * | 2008-12-05 | 2010-06-10 | Auspex Pharmaceuticals, Inc. | Quinazoline inhibitors of egfr tyrosine kinase |
| DK2468281T3 (en) | 2009-08-19 | 2016-03-21 | Eisai R&D Man Co Ltd | Quinolinderivatholdig pharmaceutical composition |
| WO2011162343A1 (ja) | 2010-06-25 | 2011-12-29 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | キナーゼ阻害作用を有する化合物の併用による抗腫瘍剤 |
| WO2012042421A1 (en) | 2010-09-29 | 2012-04-05 | Pfizer Inc. | Method of treating abnormal cell growth |
| CN103402519B (zh) | 2011-04-18 | 2015-11-25 | 卫材R&D管理有限公司 | 肿瘤治疗剂 |
| JP6038128B2 (ja) | 2011-06-03 | 2016-12-07 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | レンバチニブ化合物に対する甲状腺癌対象及び腎臓癌対象の反応性を予測及び評価するためのバイオマーカー |
| CN103127096B (zh) * | 2011-12-02 | 2015-11-25 | 杨子娇 | 吡咯基取代的吲哚类化合物在治疗青光眼病的应用 |
| US9931313B2 (en) * | 2012-04-04 | 2018-04-03 | Beth Israel Deaconess Medical Center, Inc. | Methods of treating proliferative disorders with malate or derivatives thereof |
| AU2013364953A1 (en) | 2012-12-21 | 2015-04-30 | Eisai R&D Management Co., Ltd. | Amorphous form of quinoline derivative, and method for producing same |
| EP2997377B1 (en) | 2013-05-14 | 2018-07-18 | Eisai R&D Management Co., Ltd. | Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds |
| PT3524595T (pt) | 2014-08-28 | 2022-09-19 | Eisai R&D Man Co Ltd | Derivado de quinolina altamente puro e método para produção do mesmo |
| AU2016224583B2 (en) | 2015-02-25 | 2021-06-03 | Eisai R&D Management Co., Ltd. | Method for suppressing bitterness of quinoline derivative |
| KR102662228B1 (ko) | 2015-03-04 | 2024-05-02 | 머크 샤프 앤드 돔 코포레이션 | 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합 |
| BR112017027227B1 (pt) | 2015-06-16 | 2023-12-12 | Eisai R&D Management Co., Ltd | Agente anti-câncer |
| JP6553726B2 (ja) | 2015-08-20 | 2019-07-31 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 腫瘍治療剤 |
| EP3470394B1 (en) * | 2016-06-09 | 2022-01-26 | Yuki Gosei Kogyo Co., Ltd. | Method for preparing 4-(piperidin-4-yl)morpholine |
| JP6581320B2 (ja) | 2017-02-08 | 2019-09-25 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 腫瘍治療用医薬組成物 |
| EP3624800A4 (en) | 2017-05-16 | 2021-02-17 | Eisai R&D Management Co., Ltd. | TREATMENT OF HEPATOCELLULAR CARCINOMA |
| US20220395525A1 (en) * | 2019-09-26 | 2022-12-15 | Starpharma Pty Ltd | Therapeutic dendrimer |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994003427A1 (en) * | 1992-08-06 | 1994-02-17 | Warner-Lambert Company | 2-thioindoles (selenoindoles) and related disulfides (selenides) which inhibit protein tyrosine kinases and which have antitumor properties |
| EA005032B1 (ru) * | 1998-05-29 | 2004-10-28 | Сьюджен, Инк. | Пирролзамещенные 2-индолиноны (варианты), фармацевтическая композиция (варианты), способ модулирования каталитической активности протеинкиназы, способ лечения или профилактики нарушения в организме, связанного с протеинкиназой |
| PT1233943E (pt) * | 1999-11-24 | 2011-09-01 | Sugen Inc | Formulações para agentes farmacêuticos ionizáveis como ácidos livres ou bases livres |
| EP1255536B1 (en) * | 1999-12-22 | 2006-06-28 | Sugen, Inc. | Indolinone derivatives for modulation of c-kit tyrosine protein kinase |
| SI1255752T1 (sl) * | 2000-02-15 | 2007-12-31 | Pharmacia & Upjohn Co Llc | S pirolom substituirani zaviralci 2-indolinon protein kinaza |
| MY128450A (en) * | 2000-05-24 | 2007-02-28 | Upjohn Co | 1-(pyrrolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives |
| AR042586A1 (es) * | 2001-02-15 | 2005-06-29 | Sugen Inc | 3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa |
| US6797725B2 (en) * | 2001-04-09 | 2004-09-28 | Sugen, Inc. | Prodrugs of a 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives |
-
2003
- 2003-11-13 AR ARP030104194A patent/AR042042A1/es unknown
- 2003-11-14 CA CA002506308A patent/CA2506308A1/en not_active Abandoned
- 2003-11-14 PL PL376954A patent/PL376954A1/pl not_active Application Discontinuation
- 2003-11-14 WO PCT/US2003/036526 patent/WO2004045523A2/en not_active Ceased
- 2003-11-14 TW TW092132030A patent/TW200418837A/zh unknown
- 2003-11-14 RU RU2005118417/14A patent/RU2342140C2/ru not_active IP Right Cessation
- 2003-11-14 BR BR0315630-3A patent/BR0315630A/pt not_active IP Right Cessation
- 2003-11-14 AU AU2003290943A patent/AU2003290943A1/en not_active Abandoned
- 2003-11-14 NL NL1024779A patent/NL1024779C2/nl not_active IP Right Cessation
- 2003-11-14 CN CNA2008100814220A patent/CN101259131A/zh active Pending
- 2003-11-14 CN CNB200380103225XA patent/CN100430060C/zh not_active Expired - Fee Related
- 2003-11-14 PE PE2003001154A patent/PE20040835A1/es not_active Application Discontinuation
- 2003-11-14 US US10/712,296 patent/US20040152759A1/en not_active Abandoned
- 2003-11-14 EP EP03783527A patent/EP1562600A4/en not_active Withdrawn
- 2003-11-14 MX MXPA05005150A patent/MXPA05005150A/es unknown
- 2003-11-14 PA PA20038588601A patent/PA8588601A1/es unknown
- 2003-11-14 UY UY28081A patent/UY28081A1/es not_active Application Discontinuation
- 2003-11-14 KR KR1020057008541A patent/KR20050086594A/ko not_active Ceased
- 2003-11-14 JP JP2004553729A patent/JP2006508981A/ja not_active Withdrawn
- 2003-11-14 GT GT200300245A patent/GT200300245A/es unknown
-
2005
- 2005-05-11 CO CO05045078A patent/CO5700778A2/es not_active Application Discontinuation
- 2005-05-12 ZA ZA200503841A patent/ZA200503841B/en unknown
- 2005-05-27 NO NO20052578A patent/NO20052578L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP1562600A2 (en) | 2005-08-17 |
| NO20052578L (no) | 2005-05-27 |
| US20040152759A1 (en) | 2004-08-05 |
| CN101259131A (zh) | 2008-09-10 |
| TW200418837A (en) | 2004-10-01 |
| CN100430060C (zh) | 2008-11-05 |
| RU2005118417A (ru) | 2006-01-20 |
| CA2506308A1 (en) | 2004-06-03 |
| PE20040835A1 (es) | 2004-11-18 |
| AU2003290943A1 (en) | 2004-06-15 |
| EP1562600A4 (en) | 2008-06-25 |
| MXPA05005150A (es) | 2005-07-22 |
| RU2342140C2 (ru) | 2008-12-27 |
| CN1711089A (zh) | 2005-12-21 |
| BR0315630A (pt) | 2005-08-23 |
| WO2004045523A3 (en) | 2004-09-30 |
| CO5700778A2 (es) | 2006-11-30 |
| ZA200503841B (en) | 2006-09-27 |
| KR20050086594A (ko) | 2005-08-30 |
| JP2006508981A (ja) | 2006-03-16 |
| GT200300245A (es) | 2004-06-23 |
| PA8588601A1 (es) | 2004-05-21 |
| NL1024779A1 (nl) | 2004-05-18 |
| PL376954A1 (pl) | 2006-01-09 |
| WO2004045523A2 (en) | 2004-06-03 |
| NL1024779C2 (nl) | 2004-11-09 |
| UY28081A1 (es) | 2004-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR042042A1 (es) | Administracion combinada de una indolinona con un agente quimioterapeutico para trastornos de proliferacion celular | |
| ES2524966T3 (es) | Derivados de tieno[3,2-c]piridina como inhibidores de quinasas para uso en el tratamiento del cáncer | |
| PE20250157A1 (es) | Compuestos de modulacion de kras g12d | |
| PE20191613A1 (es) | Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret | |
| AR064608A1 (es) | Derivados de pirazolo-quinazolina sustituidos, composiciones farmaceuticas que los contienen. proceso para su preparacion y uso de los mismos como agentes anticancer. | |
| PE20170003A1 (es) | Compuestos heterociclicos y usos de los mismos | |
| PE20121815A1 (es) | Compuestos de pirrolo-pirimidina como inhibidores de cdk4/6 | |
| AR092490A2 (es) | Indolil alquil amino derivados sustituidos como inhibidores de la histona desacetilasa | |
| AR097431A1 (es) | Compuestos de carboxamida de furo y tienopiridina útiles como inhibidores de quinasas pim | |
| AR041184A1 (es) | Derivados de benzopiranonas, inhibidores de las cinasas dependientes de ciclinas y su uso | |
| ECSP045253A (es) | Derivados de 5-feniltiazol y uso como inhibidores de pi3 cinasa | |
| CO6251254A2 (es) | Uso de inhibidores de piridopirimidinona de pi3k en el tratamiento del cancer | |
| MX2013005445A (es) | Pirazolopiridinas y el uso de pirazolopiridinas como inhibidores de tirosina cinasa 2 (tyk2). | |
| CY1120179T1 (el) | Ετεροκυκλικη ενωση που περιεχει αζωτο ή αλας αυτης | |
| CL2009001152A1 (es) | Compuestos derivados de n-(4-(cicloalquilo nitrogenado-1-il)-1h-pirrolo[2,3-b]piridin-3-il)amida, inhibidores de cinasa; proceso de preparacion; composicion farmaceutica; y su uso para el tratamiento de una enfermedad proliferativa. | |
| EA200900593A1 (ru) | Производные птеридина как ингибиторы polo-подобной киназы, применяющиеся при лечении рака | |
| AR087288A1 (es) | Compuestos de tetrahidropirido-piridina y tetrahidropirido-pirimidina y su uso como moduladores de receptores de c5a | |
| PE20080928A1 (es) | Derivados de anilinopiperazina como inhibidores de proteina quinasa | |
| SV2018005655A (es) | "derivados de 8-[6-[3-(amino)propoxi]-3-piridil]1-isopropilimidazo[4,5-c]quinolin-2-ona como moduladores selectivos de la cinasa de la ataxia telangiectasia mutada (atm) para el tratamiento del cancer" | |
| MX2022000550A (es) | Imidazopirimidinas como inhibidores de eed y uso de estas. | |
| PE20130306A1 (es) | Morfolinopirimidinas y su uso en terapia | |
| AR080151A1 (es) | Metodos para tratar cancer usando inhibidores de piridopirimidinona de pi 3k y mtor en combinacion con inhibidores de autofagia | |
| PE20121506A1 (es) | Compuestos triazolopiridinas como inhibidores de c-met | |
| NZ597477A (en) | Tetracyclic compounds | |
| AR047098A1 (es) | Derivados de arilanilina como agonistas del receptor adrenergico beta2 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |